Javier Rejas Gutiérrez-rekin lankidetzan egindako argitalpenak (14)

2015

  1. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors

    Annals of General Psychiatry, Vol. 14, Núm. 1

  2. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice

    Drug Design, Development and Therapy, Vol. 9, pp. 4329-4340

2013

  1. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain

    Actas Espanolas de Psiquiatria, Vol. 41, Núm. 3, pp. 164-174

  2. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs

    Annals of Clinical Psychiatry, Vol. 25, Núm. 1, pp. 17-26

  3. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain

    Social Psychiatry and Psychiatric Epidemiology, Vol. 48, Núm. 6, pp. 985-996

2012

  1. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study

    European Psychiatry, Vol. 27, Núm. 4, pp. 267-274

  2. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: A post hoc cost-effectiveness analysis in usual medical practice in Spain

    ClinicoEconomics and Outcomes Research, Vol. 4, Núm. 1, pp. 157-168

2011

  1. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use

    European Addiction Research, Vol. 17, Núm. 5, pp. 262-270

  2. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study

    European Neuropsychopharmacology, Vol. 21, Núm. 12, pp. 867-875

2010

  1. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort

    Schizophrenia Research, Vol. 119, Núm. 1-3, pp. 101-109

  2. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study

    Journal of Clinical Psychiatry, Vol. 71, Núm. 3, pp. 280-286

2008

  1. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study

    Schizophrenia Research, Vol. 104, Núm. 1-3, pp. 1-12

  2. Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study

    Schizophrenia Research, Vol. 99, Núm. 1-3, pp. 23-28

2007

  1. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study

    Schizophrenia Research, Vol. 90, Núm. 1-3, pp. 162-173